Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2026)
Lyell Immunopharma (LYEL) posted Long-Term Investments of $7.0 million for Q1 2026, down 63.4% sequentially from $19.0 million in Q3 2025, and down 63.4% YoY from $19.0 million in Q1 2025.
Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported Long-Term Investments for 7 years, with the latest figure at $7.0 million in Q1 2026.
- Quarterly Long-Term Investments fell 63.4% year-over-year to $7.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (down 63.4% YoY) and the FY2024 annual result came in at $13.0 million, down 59.33% from the prior year.
- Long-Term Investments fell to $7.0 million in Q1 2026 per LYEL's latest filing, from $19.0 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $47.0 million in Q1 2022 and troughed at $7.0 million in Q1 2026.
- A 5-year average of $26.6 million and a median of $19.0 million in 2024 frame the typical range for Long-Term Investments.
- The sharpest annual moves came in 2023 and 2024: Long-Term Investments sank 78.72% in 2023, then soared 90.0% in 2024.
- Over 5 years, Long-Term Investments stood at $44.9 million in 2022, then declined by 28.77% to $32.0 million in 2023, then tumbled by 59.33% to $13.0 million in 2024, then soared by 46.0% to $19.0 million in 2025, then slumped by 63.4% to $7.0 million in 2026.
- According to Business Quant data, Long-Term Investments over the past three periods registered $7.0 million, $19.0 million, and $19.0 million for Q1 2026, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | 23.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.90 Mn |
| Mar 31, 2026 | 6.95 Mn |
| Sep 30, 2025 | 19.00 Mn |
| Jun 30, 2025 | 19.00 Mn |
| Mar 31, 2025 | 19.00 Mn |
| Dec 31, 2024 | 13.01 Mn |
| Sep 30, 2024 | 19.00 Mn |
| Jun 30, 2024 | 19.00 Mn |
| Mar 31, 2024 | 19.00 Mn |
| Dec 31, 2023 | 32.00 Mn |
| Sep 30, 2023 | 32.00 Mn |
| Jun 30, 2023 | 36.95 Mn |
| Mar 31, 2023 | 10.00 Mn |
| Dec 31, 2022 | 44.92 Mn |
| Sep 30, 2022 | 42.00 Mn |
| Jun 30, 2022 | 47.00 Mn |
| Mar 31, 2022 | 47.00 Mn |
| Dec 31, 2021 | 47.00 Mn |
| Sep 30, 2021 | 36.40 Mn |
| Jun 30, 2021 | 83.45 Mn |